Strategy to accelerate or augment the antidepressant response and for an early onset of SSRI activity. Adjunctive amisulpride to fluvoxamine in major depressive disorder

Clinical Practice and Epidemiology in Mental Health

Volumn 6, Issue , 2010, Pages 1-3

  Carolina, Hardoy Maria ^a   Giovanni, Carta Mauro ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Antidepressant; Community survey; Epidemiology; Lifetime prevalence; Major depressive disorder

Indexed keywords

AMISULPRIDE; FLUVOXAMINE;

ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; DROWSINESS; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR DEPRESSION; TREATMENT RESPONSE;

EID: 78651234117     PISSN: None     EISSN: 17450179     Source Type: Journal    
DOI: 10.2174/17450179010060100001     Document Type: Article

References (27)

1. Brousse G, Schmitt A, Chereau I, Eschalier A, Dubray C, Llorca PM. Interest of the use of pindolol in the treatment of depression: review. Encephale 2003; 29(4 Pt 1): 338-50. (Pubitemid 37209901)
2. Kinney GG, Taber MT, Gribkoff VK. The augmentation hypothesis for improvement of antidepressant therapy: is pindolol a suitable candidate for testing the ability of 5HT1A receptor antagonists to enhance SSRI efficacy and onset latency? Mol Neurobiol 2000; 21(3): 137-52. (Pubitemid 32434067)
3. Blier P, Bergeron R, De Montigny C. Selective activation of postsynaptic 5HT-1A receptors induces rapid antidepressant response. Neuropsychopharmacology 1997; 16: 333-8. (Pubitemid 27211731)
4. De Montigny C, Blier P. Augmentation strategies in treatment resistant depression: preclinical and clinical aspects. Eur Psychiatry 1998; 13(4): S60-6.
5. Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F. Randomized double blind placebo controlled trial of pindolol in combination with fluoxetine treatment. Lancet 1997; 349: 1594-7. (Pubitemid 27229140)
6. Blier P. Neurobiological basis for the potentiation of antidepressant treatments by pindolol. Eur Neuropsychopharmacol 1998; 8(2): S96.
7. Blier P, Bergeron R. The use of pindolol to potentiate antidepressant medication. J Clin Psychiatry 1998; 59 (Suppl 5): 16-23; discussion 24-5.
8. Gardier AM, Malagi ZI, Trillat AC, Jacquot C, Artigas F. Role of 5-HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies. Fundam Clin Pharmacol 1996; 10(1): 16-27.
9. Gartside SE, Clifford EM, Cowen PJ, Sharp T. Effects of (-)-tertatolol, (-)-penbutolol and (+/-) pindolol in combination with paroxetine on presynaptic 5-HT function: an in vivo microdialysis and electrophysiological study. Br J Pharmacol 1999; 127(1): 145-52. (Pubitemid 29213243)
10. Blier P. Possible neurobiological mechanisms underlying faster onset of antidepressant action. J Clin Psychiatry 2001; 62 (Suppl 4): 7-11; discussion 37-40. (Pubitemid 32183559)
11. BZque JC, Blier P, de Montigny C, Debonnel G. Potentiation by (-)pindolol of the activation of postsynaptic 5-HT (1A) receptors induced by venlafaxine. Neuropsychopharmacology 2000; 23(3): 294-306. (Pubitemid 30609663)
12. Artigas F. Pindolol augmentation: single or multiple targets in the brain. Eur Neuropsychopharmacol 1998; 8(2): S97.
13. Zanardi R, Franchini L, Gasperini M, Lucca A, Smeraldi E, Perez J. Fluvoxamine and pindolol: a new and faster strategy in the treatment of delusional depression. Am Psychiatric Assoc Annu Meet Toronto 1998; 126.
14. Cremers TI, Wiersma LJ, Bosker FJ, den Boer JA, Westerink BH, Wikstrsm HV. Is the beneficial antidepressant effect of coadministration of pindolol really due to somatodendritic autoreceptor antagonism? Biol Psychiatry 2001; 50(1): 13-21. (Pubitemid 32701989)
15. Carta MG, Hardoy MC, Murgia S, Hardoy MJ. Major depression: strategies for an early onset of SSRI activity: adjunctive amisulpride to fluvoxamine. Psychiatric Netw 1999; 2(1): 74-6.
16. Gourion D. Antidepressants and their onset of action: a major clinical, methodological and pronostical issue. Encephale 2008; 34(1): 73-81.
17. Deshauer D, Moher D, Fergusson D, Moher E, Sampson M, Grimshaw J. Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials. CMAJ 2008; 178(10): 1293-301. (Pubitemid 351678352)
18. Katzman MA. Current considerations in the treatment of generalized anxiety disorder. CNS Drugs 2009; 23(2): 103-20.
19. Van den Berg J. Fluvoxamine versus fluoxetine: a double blind randomized comparison in major depressive episode. Am Psychiatr Assoc Ann Meet Toronto 1998; 131.
20. Pani L, Gessa GL: The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. Mol Psychiatry 2002; 7: 247-53. (Pubitemid 34280633)
21. Racagni G, Canonico PL, Ravizza L, Pani L, Amore M. Consensus on the use of substituted benzamides in psychiatric patients. Neuropsychobiology 2004; 50: 134-43. (Pubitemid 39077832)
22. Torta R, Berra C, Binaschi L, Borio R. Amisulpride in the shortterm treatment of depressive and physical symptoms in cancer patients during chemotherapies. Support Care Cancer 2007; 15(5): 539-46. (Pubitemid 46570787)
23. th ed. Text Revision (DSM IV TR), USA 2000.
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
25. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6(4): 278-96.
26. Williams JB. A structured interview guide for the Hamilton depression rating scale. Arch Gen Psychiatry 1988; 45(8): 742-47.
27. Serra G, Gessa GL. Role of mesolimbic dopamine system in the mechanism of action of antidepressant. Proc XXII CINP Copenhagen Pharmacol Toxicol 1992; 71: 72-85.